scispace - formally typeset
J

Josep Redon

Researcher at University of Valencia

Publications -  526
Citations -  96559

Josep Redon is an academic researcher from University of Valencia. The author has contributed to research in topics: Blood pressure & Population. The author has an hindex of 77, co-authored 488 publications receiving 81395 citations. Previous affiliations of Josep Redon include Population Health Research Institute & University of Milano-Bicocca.

Papers
More filters
Journal ArticleDOI

Task Force II: Blood pressure measurement and cardiovacular outcome

TL;DR: A Task Force on the prognostic significance of ambulatory blood pressure monitoring wrote this review in preparation for the Eighth International Consensus Conference and this synopsis was amended to account for opinions aired at the conference and to reflect the common ground reached in the discussions.
Journal ArticleDOI

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Andrea Rodriguez-Martinez, +1361 more
- 07 Nov 2020 - 
TL;DR: Girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries and boys in central and western Europe had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI.
Journal ArticleDOI

Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure.

TL;DR: The authors have entered a period of rapidly increasing international inequality in stroke risk, where countries with low adult mortality in the latter 20th century extended their downward trend and countries with moderate as well as high mortality have on average seen unprecedented increases in death rates from stroke.
Journal ArticleDOI

Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

TL;DR: Clinical evidence in support of RDN as an effective interventional technique in patients with resistant hypertension is conflicting; a number of observational studies and three randomized, controlled trials support both safety and efficacy of this new therapy but some smaller studies and the large, single-blind, randomized, sham-controlled symplicity HTN-3 trial failed to show superiority ofRDN when compared with medical therapy alone.